LEESOL: ₩3B Series A2 Funding for Brainwave Tech & Mental Healthcare

A South Korean mental healthcare startup, LEESOL, has secured 3 billion Korean Won (approximately $2.25 million USD) in a Series A2 bridge funding round, according to a statement released on February 19th. This investment underscores growing interest in digitally-delivered mental health solutions and the potential of neurotechnology.

Investment Details and Key Players

BNK Venture Investment led the funding round, with participation from SpaceTime Investment, Suin Venture Capital, and existing investor Vine Ventures. This brings LEESOL’s total funding to over 7.6 billion Korean Won (approximately $5.7 million USD). BNK Venture Investment’s involvement highlights the company’s recognition as a promising “baby unicorn” within the Busan region, suggesting anticipated synergy with local infrastructure and distribution networks.

Did You Know? LEESOL’s wearable device, Sleepisol, has achieved cumulative sales of over 50,000 units in Korea, the United States, and Japan.

Strategic Partnerships and Expansion

LEESOL is planning strategic collaborations to broaden its reach. A partnership with Icecream Media, a primary school digital education platform, is in development through collaboration with SpaceTime Investment. Investment from Suin Venture Capital will facilitate cooperation with a global regenerative medicine company. These partnerships suggest a strategy to integrate LEESOL’s technology into broader wellness and educational ecosystems.

LEESOL’s Technology and Products

The funding follows a Series A round of 4 billion Korean Won in 2024 and reflects market confidence in LEESOL’s core competencies: its electronic medicine (digital therapeutic technology) and personalized health management app. LEESOL combines microcurrent-based brainwave entrainment technology with AI-powered bio-signal analysis. This technology aims to address a range of mental and neurological conditions, including sleep disorders, depression, stress, and potentially even dementia prevention and chronic pain management.

The company’s flagship product, the Sleepisol series of wearable devices, utilizes proprietary technology to induce brainwave synchronization, stimulating the release of neurotransmitters to improve sleep quality and promote mental stability. Clinical trials conducted at Bundang Seoul University Hospital have been published in an SCI-level international academic journal, validating the technology’s efficacy.

Expert Insight: The increasing investment in digital therapeutics like those developed by LEESOL reflects a broader trend toward preventative and accessible mental healthcare solutions, potentially reducing reliance on traditional, often costly, clinical interventions.

Financial Performance and Future Outlook

LEESOL achieved approximately 2.6 billion Korean Won in revenue from the Sleepisol brand in 2025, with expectations exceeding 6 billion Korean Won in 2026. The company has expanded into the Japanese market through a collaboration with Funai Research Institute and plans to enter the U.S. Market starting in 2027. The Sleepisol Bio sleep and mental wellness app has surpassed 1.7 million global downloads and was recognized as a “Best App” in the Google Play Global Watch category in ten countries, including the United States, India, Indonesia, and Australia.

Recent Achievements and Investment Focus

LEESOL has recently received several accolades, including the CES 2025 Innovation Award (Sleepisol Light), selection as a “2025 Baby Unicorn” by the Ministry of SMEs and Startups, the NextRise 2025 Innovation Award, and the 2025 Venture Startup Promotion Award from the Prime Minister. The newly acquired funds will be allocated to enhancing digital therapeutic and electronic medicine technologies, developing new wellness and therapeutic devices, expanding global reach for its health management app, obtaining global certifications, aggressively entering overseas markets, and refining its AI-based mental health platform.

Frequently Asked Questions

What is LEESOL’s primary product?

LEESOL’s primary product is the Sleepisol series of wearable devices, designed to improve sleep quality and mental stability through brainwave entrainment technology.

Who led the Series A2 bridge funding round?

BNK Venture Investment led the 3 billion Korean Won Series A2 bridge funding round.

What are LEESOL’s plans for international expansion?

LEESOL has already entered the Japanese market through a collaboration with Funai Research Institute and plans to begin expanding into the U.S. Market in 2027.

As the global electronic medicine market is projected to reach approximately 51 trillion Korean Won by 2030, will LEESOL’s innovative approach to mental and neurological health redefine the future of wellness?